Daiichi Sankyo announced that Hiroyuki Okuzawa will serve as its new CEO starting on April 1, 2025. 1 The previous CEO, Sumao Manabe, DVM, PhD, will continue to serve as representative director and ...

Northern TK Venture filed a claim against Daiichi Sankyo saying the latter prevented NTK from proceeding with its open offer.

Ono picked up Romvimza—previously known by its active ingredient vimseltinib—from its $2.4 billion acquisition of Deciphera ...

Ono Pharmaceutical has secured approval from the US Food and Drug Administration (FDA) for its kinase inhibitor Romvimza ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Ono – which acquired rights to Romvimza when it bought Deciphera Pharma in a $2.4 billion deal that closed in 2023 – said ...

AstraZeneca AZN stock has risen 8.6% in the past month, mainly due to mixed fourth-quarter results and a positive update from ...

Malaysia's IHH Healthcare may be entitled to damages of up to $1.25 billion from Japan's Daiichi Sankyo for blocking its bid for control of Indian hospital operator Fortis , according to a report ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...